home / stock / pirs / pirs news

PIRS News and Press, Pieris Pharmaceuticals Inc. From 08/17/23

Stock Information
Company Name: Pieris Pharmaceuticals Inc.
Stock Symbol: PIRS
Market: NASDAQ
Website: pieris.com
Menu
PIRS PIRS Quote PIRS Short PIRS News PIRS Articles PIRS Message Board
Get PIRS Alerts

News, Short Squeeze, Breakout and More Instantly...
PIRS - Pieris gains on milestone payment from Boston Pharma

2023-08-17 10:51:44 ET More on Pieris Pharma Pieris sinks 60% as AstraZeneca halts mid-stage trial for Asthma candidate Pieris spikes 11% on data for gastric cancer candidate Pieris stock slumps ~15% after FY22 sees fall in revenue Pieris to get $5M as Seagen...
PIRS - Pieris Pharmaceuticals Announces Milestone Achievement for Boston Pharmaceuticals' Initiation of Phase 1/2 Study of BOS-342, a 4-1BB/GPC3 Immuno-Oncology Bispecific

BOSTON, MA / ACCESSWIRE / August 17, 2023 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) , a clinical-stage biotechnology company focused on novel biotherapeutics through its proprietary Anticalin ® technology platform for respiratory diseases and cancer, today announced that the Company ha...

PIRS - Pieris Pharmaceuticals Provides Strategic Update and Announces Restructuring

BOSTON, MA / ACCESSWIRE / July 18, 2023 / Pieris Pharmaceuticals, Inc. (Nasdaq:PIRS) , a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin ® technology platform for respiratory diseases and cancer, today provided a strategic update foll...

PIRS - Pieris Pharmaceuticals Announces AstraZeneca Discontinuation of Phase 2a Trial of Elarekibep (PRS-060/AZD1402) Due to New Non-Clinical Safety Findings From 13-week Toxicology Study

BOSTON, MA / ACCESSWIRE / June 21, 2023 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) , a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin ® technology platform for respiratory diseases and cancer indications, announced that partner Ast...
PIRS - Pieris Pharmaceuticals to Present at Jefferies 2023 Healthcare Conference

BOSTON, MA / ACCESSWIRE / June 2, 2023 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) , a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin ® technology platform for respiratory and cancer diseases, today announced that Stephen Yoder, p...

PIRS - Pieris Pharmaceuticals Announces Presentation of Encouraging Preclinical Data for PRS-400 at ATS 2023 International Conference

BOSTON, MA / ACCESSWIRE / May 22, 2023 / Pieris Pharmaceuticals, Inc. (Nasdaq:PIRS ), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for respiratory diseases, cancer, and other indications, announced the pre...

PIRS - Pieris Pharmaceuticals Announces Presentation of Promising Preclinical Data for PRS-220 at ATS 2023 International Conference

BOSTON, MA / ACCESSWIRE / May 21, 2023 / Pieris Pharmaceuticals, Inc. (Nasdaq:PIRS ), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for respiratory diseases, cancer, and other indications, announced the p...
PIRS - Pieris Pharmaceuticals: Expanding Elarekibep (AZD1402) Trial Finally Has Active And Completed Sites

2023-05-17 00:55:30 ET Summary Expanding Elarekibep (AZD1402) trial finally has active/completed sites. Major investment risk exists because of the Company's cash burn rate. Potential deals on PRS-220 and PRS-343 could bolster the Company's balance sheet. The Company's low...

PIRS - Best Penny Stocks to Buy? 3 Under $1 To Watch Before Next Week

2023-05-11 13:23:49 ET If you’re like most retail traders, you’re looking for ways to make money in the stock market today. With that, if you’re reading this article, it’s highly likely that you’re on the hunt for the best penny stocks to buy. In this ...

PIRS - Pieris Pharmaceuticals, Inc. (PIRS) Q1 2023 Earnings Call Transcript

2023-05-10 11:03:07 ET Pieris Pharmaceuticals, Inc. (PIRS) Q1 2023 Earnings Conference Call May 10, 2023, 08:00 AM ET Company Participants Thomas Bures - CFO Stephen Yoder - President and CEO Shane Olwill - Chief Development Officer Conference Call Particip...
Previous 10 Next 10